QuidelOrtho Corporation (QDEL)
Summary
QDEL Chart
QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns
QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.
QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?
QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.
QuidelOrtho Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 116 | $2,606.35 | $1,896.6 | -$709.75 | -27.23% |
| NA Nizar Araji National Bank Of Canada /FI/ | 234 | $4,099.68 | $2,874.69 | -$1,224.99 | -29.88% |
| BG Bart Gancher Intech Investment Management LLC | 13,253 | $381,951.46 | $162,813.1 | -$219,138.36 | -57.37% |
| JM John Malone Amundi | 22,481 | $561,169.72 | $309,113.75 | -$252,055.97 | -44.92% |
 Point72 Asset Management LP Point72 Asset Management LP | 30,422 | $499,833.47 | $435,034.6 | -$64,798.87 | -12.96% |
QuidelOrtho Corporation (QDEL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has QuidelOrtho Corporation ever had a stock split?
QuidelOrtho Corporation Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Brian J. Blaser CEO | NASDAQ (NGS) Exchange | 219798105 CUSIP |
| US Country | 6,500 Employees | - Last Dividend | - Last Split | 1 Feb 1991 IPO Date |
Overview
QuidelOrtho Corporation specializes in providing a wide range of diagnostic testing solutions aimed at enhancing patient care and health management. The company organizes its operations through four main business units: Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics, each focused on delivering innovative testing products and instrumentation across various healthcare settings. Established in 1979 and based in San Diego, California, QuidelOrtho has a global footprint, serving customers in North America, Europe, the Middle East, Africa, and China. The company leverages a mix of direct sales and distributor networks to reach its diverse customer base, which includes physician offices, hospitals, clinical laboratories, blood banks, and more, catering to both professional and over-the-counter diagnostic needs.
Products and Services
- Labs Business Unit
This division offers a comprehensive array of clinical chemistry laboratory instruments and tests for measuring bodily fluid chemicals pertinent to patient health evaluation and clinical management. It also provides immunoassay laboratory instruments and tests for detecting proteins associated with disease spread, immune responses, or organ function markers. Furthermore, the unit supplies specialized diagnostic solutions across various therapeutic areas to assist in disease detection and monitoring.
- Transfusion Medicine Business Unit
Specializing in ensuring safe blood transfusions, this unit produces immunohematology instruments and tests vital for blood typing and patient-donor compatibility. It also encompasses donor screening instruments and tests for identifying infectious diseases in blood and plasma donations, crucial for maintaining a safe blood supply.
- Point-of-Care Business Unit
This segment focuses on delivering rapid test results through instruments and tests designed for a range of point-of-care settings. These solutions are pivotal in making immediate clinical decisions, enhancing patient convenience and care quality by providing timely diagnostic information.
- Molecular Diagnostics Business Unit
At the forefront of molecular diagnostic technologies, this business unit offers advanced systems like polymerase chain reaction (PCR) thermocyclers, amplification systems, and sample-to-result molecular instruments. These products are targeted at syndromic infectious disease diagnostics, offering precise and rapid identification of pathogens to facilitate effective treatment planning.
